Immunovant, Inc.
IMVT
$31.45
-$0.16-0.51%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -147.86M | -110.64M | -126.50M | -120.61M | -106.45M |
| Total Depreciation and Amortization | 96.00K | 101.00K | 105.00K | 107.00K | 109.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.17M | 12.74M | 13.38M | 18.53M | 11.71M |
| Change in Net Operating Assets | 41.53M | 5.47M | 10.50M | -15.44M | -16.01M |
| Cash from Operations | -95.06M | -92.33M | -102.52M | -117.41M | -110.64M |
| Capital Expenditure | -8.00K | -- | -- | -- | -201.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -8.00K | -- | -- | -- | -201.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.56M | 565.19M | 24.60M | 2.92M | 450.93M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 82.00K | -586.00K | -- | -- | -319.00K |
| Cash from Financing | 3.64M | 564.60M | 24.60M | 2.92M | 450.61M |
| Foreign Exchange rate Adjustments | -988.00K | 377.00K | 878.00K | -566.00K | -488.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -92.42M | 472.66M | -77.04M | -115.06M | 339.29M |